Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Design Therapeutics Inc (DSGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: DSGN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -72.91% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 238.97M USD | Price to earnings Ratio - | 1Y Target Price 7.33 |
Price to earnings Ratio - | 1Y Target Price 7.33 | ||
Volume (30-day avg) 162747 | Beta 1.78 | 52 Weeks Range 3.15 - 7.77 | Updated Date 04/1/2025 |
52 Weeks Range 3.15 - 7.77 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.88 |
Earnings Date
Report Date 2025-03-17 | When After Market | Estimate -0.2667 | Actual -0.24 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -14.39% | Return on Equity (TTM) -19.08% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -23471437 | Price to Sales(TTM) 22642.01 |
Enterprise Value -23471437 | Price to Sales(TTM) 22642.01 | ||
Enterprise Value to Revenue 11004.35 | Enterprise Value to EBITDA -0.84 | Shares Outstanding 56762700 | Shares Floating 25381999 |
Shares Outstanding 56762700 | Shares Floating 25381999 | ||
Percent Insiders 36.36 | Percent Institutions 59.34 |
Analyst Ratings
Rating 3.33 | Target Price 7 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Design Therapeutics Inc
Company Overview
History and Background
Design Therapeutics, Inc. was founded in 2017. It is a biotechnology company focused on developing disease-modifying therapies for the treatment of serious degenerative disorders caused by inherited nucleotide repeat expansions.
Core Business Areas
- Gene Targeted Chimeras (GeneTACs): Development of novel, small molecule GeneTACs designed to selectively target and degrade disease-causing RNA. The company is focused on creating treatments for nucleotide repeat expansion disorders, including Friedreich's ataxia (FA) and myotonic dystrophy type 1 (DM1).
Leadership and Structure
Andranik Yessayan is the CEO. The company has a board of directors and a typical organizational structure for a biotech company, including research and development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- GeneTACs for Friedreich's Ataxia (FA): Design Therapeutics' lead program targets Friedreich's ataxia. This is currently in pre-clinical and early clinical phases, and there is no current market share data available as there are no approved therapies with the same mechanism of action. Competitors developing FA therapies include Larimar Therapeutics (LRMR) and Retrotope.
- GeneTACs for Myotonic Dystrophy Type 1 (DM1): Another focus is on DM1, which also utilizes the GeneTAC approach. Similar to FA, this is in early stages, and market share data is not applicable. Competitors working in DM1 include Avidity Biosciences (RNA) and Ionis Pharmaceuticals (IONS).
Market Dynamics
Industry Overview
The company operates in the biotechnology industry, specifically within the area of RNA-targeted therapeutics. This industry is characterized by high risk, high reward, significant investment in research and development, and a long regulatory approval pathway.
Positioning
Design Therapeutics is positioning itself as a leader in the development of GeneTACs for treating inherited nucleotide repeat expansion disorders. Its competitive advantage lies in its proprietary GeneTAC platform and its focus on addressing diseases with significant unmet medical needs.
Total Addressable Market (TAM)
The total addressable market for Friedreich's ataxia and myotonic dystrophy type 1 is estimated to be in the billions of dollars. Design Therapeutics is aiming to capture a significant portion of this TAM by developing disease-modifying therapies.
Upturn SWOT Analysis
Strengths
- Proprietary GeneTAC platform technology
- Focus on addressing diseases with high unmet medical needs
- Strong intellectual property position
- Experienced management team
Weaknesses
- Early stage of development (high clinical trial risk)
- Dependence on GeneTAC platform success
- Limited financial resources compared to larger pharmaceutical companies
- No currently approved products
Opportunities
- Potential to expand GeneTAC platform to other diseases
- Partnerships with larger pharmaceutical companies
- Accelerated regulatory pathways for rare diseases
- Positive clinical trial results could lead to rapid value appreciation
Threats
- Clinical trial failures
- Competition from other companies developing RNA-targeted therapies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- IONS
- LRMR
- RNA
Competitive Landscape
Design Therapeutics has a strong advantage in its GeneTAC platform, however other companies have existing products or more advanced clinical trials targeting similar diseases.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Since its founding in 2017, Design Therapeutics has focused on preclinical development. Growth is tied to advancing their GeneTAC platform and progressing compounds through clinical trials.
Future Projections: Future growth projections depend on clinical trial results and regulatory approvals. Analyst estimates suggest significant upside potential if clinical trials are successful.
Recent Initiatives: Recent initiatives include advancing their Friedreich's ataxia (FA) program into clinical trials, developing new GeneTACs for other disease targets, and strengthening their intellectual property portfolio.
Summary
Design Therapeutics is a promising early-stage biotech company with a novel platform technology. Its success is highly dependent on the success of its clinical trials. The company faces significant competition and regulatory hurdles, but positive clinical results could lead to significant value creation. The company needs to look out for clinical trial failures which would have an adverse affect on the company and it needs to secure partnerships to further leverage its platform.
Similar Companies
- IONS
- RNA
- LRMR
Sources and Disclaimers
Data Sources:
- Design Therapeutics Inc. Website
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share and TAM are estimates and may vary. Financial data is not real-time and may be outdated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Design Therapeutics Inc
Exchange NASDAQ | Headquaters Carlsbad, CA, United States | ||
IPO Launch date 2021-03-26 | Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson Mr. Pratik Shah Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 54 | Website https://www.designtx.com |
Full time employees 54 | Website https://www.designtx.com | ||
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.